Ordering Recommendation




Semi-Quantitative Ex Vivo Challenge/Cell Culture/Quantitative Enzyme-Linked Immunosorbent Assay/Quantitative Chemiluminescent Immunoassay


Mon, Fri


11-14 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Patients taking calcineurin inhibitors should stop their medication 72 hours prior to draw. Patients on prednisone should be off their medication for 2 weeks prior to draw.


Plain red.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport tube and freeze immediately (Min: 0.5 mL) AND transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature

First Specimen: CRITICAL FROZEN. Separate specimens must be submitted for this multiple test panel.
Second Specimen:

Unacceptable Conditions

Specimens other than serum. Contaminated, grossly hemolyzed, or lipemic specimens.


First Specimen: After separation from cells: Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Second Specimen: After separation from cells: Ambient: 8 hours; Refrigerated: 1 Week; Frozen: 6 months

Reference Interval

By report

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)


1) Chronic urticaria (CU) is a common and complex dermatological condition that is suspected when patients experience persistent hives for over 6 weeks. No published evidence of an exogenous allergen as the cause of this disorder exists. About 45 percent of cases have autoantibodies directed against either basophil or mast cell-associated IgE or the high affinity IgE-Fc receptor (Fc epsilon R1 alpha) (Clin Exp Allergy 2009; 39: 777-87

2) The presence of histamine-releasing factors (including but not limited to IgE and Fc epsilon R1 alpha-specific autoantibodies) in the patient serum can be indirectly determined by evaluating basophil/mast cell activation status using histamine-release assays, autologous serum-skin test, and flow cytometric measurement of the basophil and mast cell-specific marker CD203c. Serum from CU patients can activate donor basophils, which induces histamine release and CD203c upregulation (J Allergy Clin Immunol 2006; 117: 1430-4).

Hotline History


CPT Codes

86352; 86800; 84443; 86376


Component Test Code* Component Chart Name LOINC
0050075 Thyroid Peroxidase (TPO) Antibody 8099-4
0050105 Thyroglobulin Antibody 8098-6
0070145 Thyroid Stimulating Hormone 3016-3
2005414 Urticaria-Inducing Activity 63369-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Chronic Urticaria
  • Chronic Urticaria Panel
  • urticaria-inducing activity, TPO, TSH, Tg antibodies
Urticaria-Inducing Activity with Thyroid Antibodies and Stimulating Hormone